Evidence map›Paper›PMID 25622198›Full record

Trial reportJournal of consulting and clinical psychology2015

Concurrent alcohol and tobacco treatment: Effect on daily process measures of alcohol relapse risk.

Ned L Cooney, Mark D Litt, Kevin A Sevarino, Lucienne Levy, Linda S Kranitz, Helen Sackler, Judith L Cooney

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of consulting and clinical psychology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Psycho-oncology · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders.Alcohol and alcoholism (Oxford, Oxfordshire) · 2022
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ned L CooneyVA Connecticut Healthcare System.
Mark D LittDivision of Behavioral Sciences and Community Health, University of Connecticut Health Center.
Kevin A SevarinoVA Connecticut Healthcare System.
Lucienne LevyDepartment of Psychiatry, Yale University School of Medicine.
Linda S KranitzDepartment of Psychiatry, Yale University School of Medicine.
Helen SacklerDepartment of Psychiatry, Yale University School of Medicine.
Judith L CooneyVA Connecticut Healthcare System.
VA Connecticut Healthcare System · USYale University · USUConn Health · US

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
FIELD STUDY OF SMOKING CESSATION IN ALCOHOLISM TREATMENTR01AA011197 · NIAAA · YALE UNIVERSITY · PI COONEY, NED L · 1997 to 2011
$4.3M
NCATS NIH HHS UL1 TR000142NIAAA NIH HHS R01 AA011197NIAAA NIH HHS R01AA011197
6 · The paper itself

Abstract

objectiveThe aim of this study was to compare the effects of alcohol treatment along with concurrent smoking treatment or delayed smoking treatment on process measures related to alcohol relapse risk.

methodAlcohol dependent smokers (N = 151) who were enrolled in an intensive outpatient alcohol treatment program and were interested in smoking cessation were randomized to a concurrent smoking cessation (CSC) intervention or to a waiting list for delayed smoking cessation (DSC) intervention scheduled to begin 3 months later. Daily assessments of relapse process measures were obtained using an Interactive Voice Response (IVR) system for 12 weeks after the onset of smoking treatment in the CSC condition, and before beginning smoking treatment in the DSC condition. Smoking outcomes were assessed at 2 and 13 weeks after starting treatment.

resultsSeven-day carbon monoxide (CO) verified smoking abstinence in the CSC condition was 50.5% at 2 weeks and 19.0% at 13 weeks compared with 2.2% abstinence at 2 weeks and 0% abstinence at 13 weeks for those in the DSC condition. Drinking outcomes were not significantly different for CSC versus DSC treatment conditions. On daily IVR assessments, CSC participants had significantly lower positive alcohol outcome expectancies relative to DSC participants. Multilevel modeling (MLM) analyses of within-person effects across the 12 weeks of daily monitoring showed that daily smoking abstinence was significantly associated with same day reports of lower alcohol consumption, lower urge to drink, lower negative affect, lower positive alcohol outcome expectancies, greater alcohol abstinence self-efficacy, greater alcohol abstinence readiness to change, and greater perceived self-control demands.

conclusionsAnalyses of process measures provide support for recommending smoking intervention concurrent with intensive outpatient alcohol treatment. (PsycINFO Database Record

Indexed as

Self EfficacyAdultAlcoholismAmbulatory CareFemaleHumansMaleMiddle AgedOutpatientsRecurrenceRiskRisk AssessmentSmokingSmoking CessationTime FactorsTreatment Outcome

Identifiers

PMID25622198
PMCPMC4380705
OpenAlexW2160071302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.